Elevation Oncology, Inc.
ELEV · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.04 | -0.03 | 0.19 |
| FCF Yield | -82.91% | -30.67% | -23.64% | 0.00% |
| EV / EBITDA | 0.98 | -1.58 | -1.38 | -12.80 |
| Quality | ||||
| ROIC | -18.24% | -11.68% | -13.19% | -9.81% |
| Gross Margin | 0.00% | 50.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.89 | 0.98 | 0.65 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | 336,097.54% | 336,097.54% | 386,987.66% | 386,987.66% |
| Free Cash Flow Growth | -24.59% | -21.71% | 0.00% | 100.00% |
| Safety | ||||
| Net Debt / EBITDA | 2.06 | 1.94 | 1.30 | 2.60 |
| Interest Coverage | -15.42 | -11.11 | -13.27 | -11.03 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -8,856.00 | -2,647.89 | -47,358.00 | -7,740.00 |